Reviva Pharmaceuticals Holdings, Inc. (RVPH): Shareholders' Equity
$8.65M
As of 2025-12-31
$15.21M
As of 2026-06-30
+1.0%
3-year compound annual growth
+9.6%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.65M | +964.2% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $812.6K | -85.8% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $5.72M | n/a | 2025-04-03, Balance as of period end |
| 2023-09-30 | -$12.81M | n/a | 2024-04-15, Balance as of period end |
| 2023-06-30 | -$1.82M | n/a | 2024-04-15, Balance as of period end |
| 2023-03-31 | $1.61M | n/a | 2024-04-15, Balance as of period end |
| 2022-12-31 | $8.39M | n/a | 2024-04-15, Balance as of period end |
| 2022-09-30 | $17.56M | n/a | 2024-04-15, Balance as of period end |
| 2021-12-31 | $28.69M | +424.8% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $5.47M | n/a | 2022-03-15, Balance as of period end |
| 2020-02-29 | $5.00M | n/a | 2020-05-04, Balance as of period end |
| 2019-12-31 | -$6.81M | n/a | 2021-05-07, Balance as of period end |
| 2019-02-28 | $5.00M | n/a | 2020-05-04, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Reviva Pharmaceuticals Holdings, Inc. (RVPH) | 2025-12-31 | $8.65M | +964.2% |
| Aprea Therapeutics, Inc. (APRE) | 2025-12-31 | $12.44M | -35.6% |
| Anixa Biosciences Inc (ANIX) | 2025-10-31 | $15.16M | -24.2% |
| Synlogic, Inc. (SYBX) | 2025-12-31 | $11.86M | -7.0% |
| Aditxt, Inc. (ADTX) | 2025-12-31 | $5.61M | +235.0% |
| Cingulate Inc. (CING) | 2025-12-31 | $2.51M | -66.3% |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $8.54M | -40.3% |
| Tempest Therapeutics, Inc. (TPST) | 2025-12-31 | $6.67M | -65.1% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $14.48M | -31.1% |
Compare RVPH, APRE, ANIX, SYBX side by side · Screen every company in Pharmaceutical Preparations ↗